NAM
AUPH icon

NTV Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

NTV Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,000
Closed -$94K – 184
2017
Q3 		$94K Buy
+15,000
New +$94.6K 0.03% 180

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

NTV Asset Management's AUPH Position: Q4 2017 in Review

NTV Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2017, closing a stake of 15,000 shares — an estimated $94K sold.

NTV Asset Management first reported a position in AUPH in Q3 2017 and held it in 1 quarter. The position peaked at $94K in Q3 2017. 68 funds tracked by Wall St. Rank hold AUPH as of Q4 2017.

  • NTV Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • NTV Asset Management sold 15,000 Aurinia Pharmaceuticals shares in Q4 2017, an estimated $94K.
  • NTV Asset Management first reported a position in Aurinia Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • NTV Asset Management's Aurinia Pharmaceuticals position peaked at $94K in Q3 2017.
  • 68 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2017.

Based on NTV Asset Management's 13F filing for Q4 2017, filed 6 Feb 2018.